专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090176220A1 ANTIBODY CHARACTERIZATION TEST 审中-公开
标题翻译：抗体特征测试
公开(公告)号：US20090176220A1
公开(公告)日：2009-07-09
申请号：US12097084
申请日：2006-12-15
申请人： Frederic Dhainaut , Jean-Luc Teillaud , Laurent Siret
发明人： Frederic Dhainaut , Jean-Luc Teillaud , Laurent Siret
IPC分类号： C12Q1/68 , C12Q1/02
CPC分类号： C07K16/00 , A61K39/39591 , C07K2317/41 , G01N33/536 , G01N33/6854
摘要： The present invention relates to a method for measuring the ability of an antibody preparation to activate an Fc receptor, wherein this method comprises the following steps: a) aggregating said antibodies with one another, b) bringing cells expressing an Fc receptor into contact with said aggregated antibodies, and c) measuring the reaction of the cells resulting from the activation of the Fc receptor of said cells by the Fc region of said antibodies.
摘要翻译：本发明涉及一种测定抗体制剂活化Fc受体的能力的方法，其中该方法包括以下步骤：a）将所述抗体彼此聚集，b）使表达Fc受体的细胞与所述聚集的抗体，和c）测量由所述抗体的Fc区激活所述细胞的Fc受体产生的细胞的反应。

2. 发明授权

US07790399B2 Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors 失效
标题翻译：制备与Fcγ受体具有不同结合特征的人，人源化或嵌合抗体或多肽
公开(公告)号：US07790399B2
公开(公告)日：2010-09-07
申请号：US10551819
申请日：2004-04-05
申请人： Dominique Bourel , Christophe De Romeuf , Sophie Siberil , Wolf Herman Fridman , Jean-Luc Teillaud , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Christophe De Romeuf , Sophie Siberil , Wolf Herman Fridman , Jean-Luc Teillaud , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： G01N33/53
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/2833 , C07K16/34 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The present invention relates to a method for the production and the selection of human or chimæric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).
摘要翻译：本发明涉及一种生产和选择包含能够调节一种或几种特定Fc受体的活性的人IgG的Fc区的人或小鼠或人源化抗体或分子的方法，例如触发抑制性通过IgG的人类IIB受体（FcgammaRIIB / CD32）起作用。

3. 发明申请

US20090202979A1 Production of antibody formats and immunological applications of said formats 有权
标题翻译：所述形式的抗体形式和免疫应用的生产
公开(公告)号：US20090202979A1
公开(公告)日：2009-08-13
申请号：US11818218
申请日：2007-06-13
申请人： Daniel Baty , Ghislaine Behar , Martine Chartier , Andre Pelegrin , Jean-Luc Teillaud , Isabelle Teulon
发明人： Daniel Baty , Ghislaine Behar , Martine Chartier , Andre Pelegrin , Jean-Luc Teillaud , Isabelle Teulon
IPC分类号： A01N1/02 , C07K16/46 , C12N15/63 , C07H21/04
CPC分类号： C07K16/3007 , C07K16/00 , C07K16/283 , C07K2317/21 , C07K2317/22 , C07K2317/24 , C07K2317/52 , C07K2317/522 , C07K2317/53 , C07K2317/54 , C07K2317/55
摘要： The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
摘要翻译：本发明涉及将目标基因组修饰引入卵母细胞或卵中的体外方法以及用于在宿主细胞的基因组中进行随机插入的方法。

4. 发明申请

US20070135621A1 Therapeutic products with enhance ability to immunomodulate cell functions 失效
标题翻译：具有增强免疫细胞功能的能力的治疗产品
公开(公告)号：US20070135621A1
公开(公告)日：2007-06-14
申请号：US10551819
申请日：2004-04-05
申请人： Dominique Bourel , Christophe De Romeuf , Sophie Siberil , Wolf Fridman , Jean-Luc Teillaud , Nicolas Bihoreau , Emmanuel Nony
发明人： Dominique Bourel , Christophe De Romeuf , Sophie Siberil , Wolf Fridman , Jean-Luc Teillaud , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： C07K16/44 , G01N33/567 , C12P21/04 , C12N5/06
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/2833 , C07K16/34 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The present invention relates to a method for the production and the selection of human or chimaeric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).
摘要翻译：本发明涉及一种生产和选择包含能够调节一种或几种特定Fc受体活性的人或人源化抗体或分子的方法，所述方法包括人IgG的Fc区，例如触发抑制性通过IgG的人类IIB受体（FcgammaRIIB / CD32）起作用。

5. 发明授权

US09234045B2 Monoclonal antibody directed against CD20 antigen 有权
标题翻译：针对CD20抗原的单克隆抗体
公开(公告)号：US09234045B2
公开(公告)日：2016-01-12
申请号：US11793138
申请日：2005-12-14
申请人： Christophe De Romeuf , Christine Gaucher , Jean-Luc Teillaud , Jean-François Prost
发明人： Christophe De Romeuf , Christine Gaucher , Jean-Luc Teillaud , Jean-François Prost
IPC分类号： C07K16/30 , A61K39/395 , C12N5/12 , C07K16/28 , A61K51/10 , A61K39/00
CPC分类号： C07K16/2887 , A61K51/1069 , A61K2039/505 , A61P35/02 , A61P37/00 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C12N2510/02
摘要： The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of FcγRIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.
摘要翻译：本发明涉及针对CD20抗原的单克隆抗体，用于对人的治疗性施用，其中抗体的每个轻链由鼠 - 人嵌合核酸序列SEQ ID No 27编码，并且每个重链抗体的编码由SEQ ID No.19的鼠 - 人嵌合核酸序列编码。本发明还涉及用抗体体外激活免疫效应细胞中的FcγRIIIA受体的方法和治疗表达CD20的白血病或淋巴瘤的方法与抗体。

6. 发明申请

US20090053233A1 Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations 有权
标题翻译：针对B型淋巴细胞增生的细胞毒性抗体
公开(公告)号：US20090053233A1
公开(公告)日：2009-02-26
申请号：US11793138
申请日：2005-12-14
申请人： Christophe De Romeuf , Christine Gaucher , Jean-Luc Teillaud , Jean-Francois Prost
发明人： Christophe De Romeuf , Christine Gaucher , Jean-Luc Teillaud , Jean-Francois Prost
IPC分类号： A61K39/395 , C07K16/18 , C12N15/64 , A61P35/00 , C12N5/16 , C07H21/00
CPC分类号： C07K16/2887 , A61K51/1069 , A61K2039/505 , A61P35/02 , A61P37/00 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C12N2510/02
摘要： The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of FcγRIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma.
摘要翻译：本发明涉及针对CD20抗原的单克隆抗体，其中每条轻链的可变区由与SEQ ID No.5的小鼠核酸序列具有至少70％同一性的序列编码，所述变体每个重链的区域由与小鼠核酸序列SEQ ID No.7具有至少70％同一性的序列编码，其轻链和重链的恒定区是来自非鼠类物种的恒定区，以及用于激活免疫效应细胞中的FcγRIIIA受体，以及用于制造特别用于治疗白血病或淋巴瘤的药物。

7. 发明申请

US20090029393A1 METHOD FOR PREPARING ANTIBODIES SELECTIVE FOR ACTIVATING FC RECEPTORS 审中-公开
标题翻译：制备选择性用于激活FC受体的抗体的方法
公开(公告)号：US20090029393A1
公开(公告)日：2009-01-29
申请号：US12097022
申请日：2006-12-15
申请人： Jean-Luc Teillaud , Sylvie Jorieux , Sophie Siberil , Renee Menez , Enrico Stura , Frederic Ducancel
发明人： Jean-Luc Teillaud , Sylvie Jorieux , Sophie Siberil , Renee Menez , Enrico Stura , Frederic Ducancel
IPC分类号： G01N33/566 , C07K16/18
CPC分类号： C07K16/00 , C07K16/34 , C07K2317/52 , C07K2317/71
摘要： The present invention relates to a method for preparing an antibody selective for activating antibody Fc region receptors (FcRs) comprising an ITAM motif or motifs (immunoreceptor tyrosine-based activation motif), comprising the steps of obtaining monoclonal antibodies from a hybridoma, from a heterohybridoma or from any animal, plant or human cell line, replacing each of the His 310 and His 435 residues (Cabat numbering) of the Fc region of said antibody with a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, and then selecting the antibodies for which the binding to inhibitory FcRs comprising ITIM motifs (immunoreceptor tyrosine-based inhibition motif) is decreased by at least 30%, preferably by at least 50%, 70%, 80% or else by at least 90% relative to the same antibody having a natural Fc region. The present invention also relates to the use of an antibody derived from the method of the invention in the production of a medicament for use in particular in the treatment of cancer and of infectious pathologies.
摘要翻译：本发明涉及一种制备用于激活包含ITAM基序或基序（基于免疫受体酪氨酸的激活基序）的抗体Fc区受体（FcR）的选择性抗体的方法，该方法包括以下步骤：从杂交瘤获得来自杂交瘤的单克隆抗体或来自任何动物，植物或人类细胞系，用选自赖氨酸，丙氨酸，甘氨酸，缬氨酸，亮氨酸，异亮氨酸，脯氨酸的残基替代所述抗体的Fc区的每个His 310和His 435残基（Cabat编号），甲硫氨酸，色氨酸，苯丙氨酸，丝氨酸或苏氨酸，然后选择与包含ITIM基序（基于免疫受体酪氨酸的抑制基序）的抑制性FcR结合的抗体降低至少30％，优选至少50％，70 ％，80％或者至少90％，相对于具有天然Fc区的相同抗体。本发明还涉及衍生自本发明方法的抗体在制备特别用于治疗癌症和感染性病理学的药物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式